Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2017-05-11 Report Publication Anno…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Communiqués de mise à disposition de documents / Modalités de mise à disposition du rapport financier annuel
Report Publication Announcement Classification · 1% confidence The document is a short announcement (2687 characters) from ABIVAX stating that their 'Document de Référence 2016' (Annual Reference Document) has been made available to the public and filed with the AMF. It provides instructions on how to access the report online or at their office. Per the 'Menu vs Meal' rule, this is an announcement of a report's publication, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2017-05-11 French
Document availability communications / Annual financial report
Report Publication Announcement Classification · 1% confidence The document is titled "ABIVAX announces the publication of its 2016 Registration Document...". It explicitly states that the 2016 Registration Document, which includes the Annual Financial Report and clinical trial results, has been filed with the French Market Authority (AMF). The document itself is short (2529 characters) and serves primarily to announce that the main report is available elsewhere ('Copies of this document are available... online on the Company's website'). According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report has been published points towards a Report Publication Announcement (RPA). While the content relates to an Annual Report (10-K), the document's function here is the announcement of its publication.
2017-05-11 English
Rapport financier annuel
Annual Report Classification · 1% confidence The document is a 'Document de Référence' (Reference Document) for the year 2017, registered with the French Autorité des marchés financiers (AMF). In the French regulatory context, a 'Document de Référence' serves as the equivalent of an Annual Report (10-K), containing comprehensive financial statements, management reports, risk factors, governance details, and audit information for the fiscal year. It is a substantive, long-form annual disclosure document, not a mere announcement or summary. FY 2017
2017-05-11 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references regulatory articles from the French AMF (Autorité des marchés financiers) and provides a table detailing the number of shares and voting rights as of a specific date (28/04/2017). This content directly relates to changes in share structure and voting power, which falls under notifications regarding share capital changes or major shareholdings. Since the document is a direct publication of this specific data, it aligns best with 'Share Issue/Capital Change' (SHA) or 'Major Shareholding Notification' (MRQ). Given the focus on the total number of shares and voting rights, which is a fundamental capital structure metric often required for regulatory disclosure, SHA is the most precise fit, although MRQ is also plausible if this is a threshold crossing report. However, the structure is a standard disclosure of total capital/voting rights, which is often mandated alongside capital changes or as a periodic update related to capital structure. Comparing the definitions, SHA (Share Issue/Capital Change) covers capital structure changes, and this is a direct report on the current capital structure. MRQ is specifically for *changes* in *significant share ownership levels*. Since this reports the total, SHA is slightly better, but the closest category that captures this specific type of regulatory disclosure about the total share count is often grouped with capital structure updates. Let's re-evaluate against the options. This is a mandatory disclosure under French law (L. 233-8 II du code de commerce). It is not a dividend (DIV), director dealing (DIRS), or proxy solicitation (PSI). It is a direct report of capital structure data. SHA seems the most appropriate fit for a formal disclosure of the total share count and voting rights.
2017-05-11 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Earnings Release Classification · 1% confidence The document is a press release dated May 2nd, 2017, announcing preliminary clinical trial results for the drug candidate ABX464 concerning the reduction of HIV reservoirs. It details trial methodology (Phase IIa), safety, efficacy data (mean change in viral DNA copies), and future plans (next steps, additional trials). It concludes with contact information and webcast details. This format—a formal announcement of scientific/clinical progress, often released before a full regulatory filing or earnings report—is characteristic of an Earnings Release (ER) or a general press announcement. Since it focuses heavily on clinical trial results and is not a transcript (CT), a formal annual report (10-K), or a dedicated investor presentation (IP), it best fits the 'Earnings Release' category, which covers initial announcements of periodical results/developments, even if not strictly quarterly earnings. Given the context of a major scientific/clinical milestone announcement, ER is the most appropriate fit among the provided options, as it serves as the primary public disclosure of performance-related news. FY 2017
2017-05-02 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Earnings Release Classification · 1% confidence The document is a press release dated May 2, 2017, announcing preliminary clinical trial results (Phase IIa study ABX464-004) regarding the reduction of HIV reservoirs using the drug ABX464. It details study design, safety, efficacy data (reduction in viral DNA copies), and future plans (study ABX464-005). This content structure—announcing key scientific/clinical findings and financial/operational updates via a formal press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a detailed announcement of specific results rather than a general regulatory filing fallback, and it focuses on periodic performance/results (even if clinical trial results rather than quarterly financials), it aligns best with the 'Earnings Release' category, which often encompasses major operational/clinical milestones announced via press release. Given the context of a biotech company announcing trial results, this functions as their primary periodic update on progress, similar to an ER. It is not a full Annual Report (10-K), a specific Audit Report (AR), or a Call Transcript (CT). It is a formal announcement of results, making ER the most appropriate fit over the general RNS. FY 2017
2017-05-02 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.